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  Abstract	  	  Conformationally	  constrained	  bicyclic	  amino	  acids	  are	  invaluable	  in	  the	  synthesis	  of	  natural	  products	  and	  peptidomimetics.	  Aeruginosins	  contain	  novel	  bicyclic	  amino	  acid,	  2-­‐carboxy-­‐6-­‐hydroxyl	   octahydrindole	   (Choi)	   as	   the	   core	   structure.	   Aeruginosins	  are	  tetra	  peptide	  serine	  protease	  inhibitors	  isolated	  from	  marine	  sponges	  and	  cyanobacterial	  water	  blooms.	   Rigid	   bicyclic	   amino	   acid	   (Choi)	   is	   an	   essential	   core	  structure,	   which	   strongly	  influence	   biological	   activity	   of	   aeruginosin	   family	   members.	   Aeruginosins	   showed	  promising	   inhibitory	   activity	   against	   thrombin,	   trypsin,	   and	  factor	  VIIa.	   Thrombin	  and	  factor	  VIIa	   play	   a	  major	  role	   in	   blood	   clotting	   cascade;	   excessive	   coagulation	   lead	   to	  thrombosis	   and	   other	   cardiovascular	   diseases.	   Several	   research	   groups	   have	   reported	  a	  number	  of	  synthetic	  aeruginosin	   analogs.	   In	   this	   thesis,	   some	   of	   the	   synthetic	  methodologies	   of	   bicyclic	   amino	   acid	   core	   of	   aeruginosins	  are	   presented.	   Importance	   of	  bicyclic	  amino	  acids	  in	  peptidomimetic	  synthesis	  and	  drug	  designing	  is	  presented.	  Mainly,	  syntheses	   of	  ring	  oxygenated	   Choi	   analogs	   starting	   from	   glucose	   and	   mannose	  are	  presented. 	  	  
Key	  words:	  Bicyclic	  amino	  acid,	  2-­‐carboxy-­‐6-­‐hydroxyl	  octahydrindole	  (L-­‐Choi),	  ring	  oxygenated	  carboxy	  octahydrindole	  	  (O-­‐Choi),	  aeruginosins,	  thrombin	  and	  peptidomimetics.
1	  	  
Chapter	  1:	  Literature	  review	  on	  bicyclic	  amino	  acids	  	  	  
Introduction:	  	   Conformationally	   constrained	   bicyclic	   compounds	   have	   been	   invaluable	   in	  medicinal	  chemistry.	  Plenty	  of	  biologically	  significant	  natural	  products	  and	  their	  synthetic	  analogs	  possess	  various	  bicyclic	   scaffolds	   as	   the	   core	   structure.	  Especially,	   bicyclic	   amino	  acids	   are	   prominent	  building	   blocks	  in	   the	  synthesis	  of	   peptidomimetics	   and	   natural	  product	   analogs.	   Aeruginosin	   family	   members	   are	  natural	   product	  tetra	  peptides	  comprised	  of	  2-­‐carboxy-­‐6-­‐hydroxyoctahydrindole	  (Choi)	  or	  analogs	  of	  Choi.	  Promising	  anti-­‐thrombin	  activity	  of	  aeruginosin	  family	  members	  made	  them	  attractive	  new	  class	   of	   small	   molecule	   anticoagulant	   drug	   targets.	   Several	   research	   groups	   have	   been	  pursuing	  synthesis	  of	   aeruginosin	   analogs	   and	   their	   core	  structure;	   some	   of	  the	  significant	  efforts	  will	   be	   discussed	  in	   this	   chapter.	   Conformationally	   constrained	  bicyclic	  amino	  acids	  provide	  many	  advantages	  such	  as	  preventing	  metabolic	  degradation	  of	  small	   molecule	  peptides.	   Hence	   bicyclic	   amino	   acids	   have	   been	   continuously	   receiving	  considerable	  attention	  from	  synthetic	  community.	  However,	  it	  is	  not	  possible	  to	  discuss	  all	  classes	   of	   bicyclic	   amino	   acids,	   mainly	   octahydrindole	   derivatives	   and	   azabicyclo	   amino	  acid	  analogs	  will	  be	  discussed. 	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Bicyclic	  amino	  acids	  in	  peptidomimetics	  
	   Peptidomimetic	   compounds	   are	   molecules	   whose	   essential	   elements	  (pharmacophores)	   mimic	   a	   natural	   peptide	   or	   protein	   in	  three-­‐dimensional	  space	   and	  which	   retain	   the	   ability	   to	   interact	   with	   the	   biological	  target	  and	   produce	   the	   same	  biological	  effect.	  Peptide	  motifs	  are	  present	  in	  many	  biologically	  active	  molecules.1-­‐3	  Drug	  design	   often	   involves	   the	  examination	  of	   protein-­‐protein	   interactions	   associated	  with	  disease,	   followed	   by	   the	  design	  of	   small	   molecules	   that	   can	   bind	   to	   one	   of	   the	  interacting	  proteins.	  Often,	  the	  biological	  activity	  of	  proteins	  stems	  from	  a	  small-­‐localized	  region	  of	  a	  protein	  surface	  created	  by	  secondary	  structural	  elements	  such	  as	  beta	  strand.	  Despite	   their	  remarkable	  activities	   in	  enzymatic	  or	  receptor-­‐based	  assays,	  peptides	  suffer	  from	   a	   number	   of	   disadvantages	   that	  compromise	  their	   use	   as	   drugs.4-­‐6	   Linear	   peptide	  molecules	  possess	  greater	  flexibility	  to	  adopt	  random	  conformations	  and	  compromise	  their	  biological	   activity.	   Peptide	  molecules	   are	   prone	   to	  rapid	  metabolic	   degradation;	   they	   are	  rapidly	  excreted	  through	  the	  liver	  and	  kidney,	  which	  contribute	  to	  their	  exclusion	  as	  drug	  substance	  in	  clinical	  practice.	  	   	  A	  synthetic	  peptidomimetic	   that	   is	   not	   subject	   to	   cleavage	   while	   maintaining	   the	  biological	  activity	  of	  the	  original	  peptide	  may	  have	  distinct	  advantages	  as	  a	  potential	  drug	  substance.	  Conformationally	  pre-­‐organized	  or	   fixed	   into	   a	  shape	  that	  is	   recognized	  by	   a	  receptor	  can	  have	  higher	  affinity	   for	   that	  receptor,	  also	  have	  reduced	  entropy.	  Successful	  chemical	  modification	  approaches	  are	   involved	  in	   the	  restriction	  of	   conformations	   by	  the	  cyclization	  of	  peptides	  or	   the	   incorporation	   of	  conformationally	  restricted	  building	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blocks.7,	  8	  Naturally	  occurring	  amino	  acids	  in	  a	  potential	  inhibitor	  molecule	  can	  be	  replaced	  by	   conformationally	   constrained	  monocyclic	   and	   bicyclic	   unnatural	   amino	   acids	   to	   avoid	  metabolic	   degradation	   and	   maintain	   its	   biological	   activity.	  It	   may	   also	   exhibit	  enhanced	  potency	  over	  their	  parent	  sequences,	  and	  more	  importantly,	  it	  avoids	  undesired	  side	  effects	  from	  byproducts	  of	  peptide	  degradation.9-­‐11 	  	  
	  
	  
Figure	  1.1.	  Possible	  conformations	  of	  bicyclo	  (3.3.0)octane	  	  	   Bicyclic	   skeletons	   like	  bicyclo(3.3.0)octane	   (Fig.	   1)	  is	  interesting	  because	   it	   has	   a	  rigid	  ring	   junction	  as	  well	  as	  conformationally	  flexible	  ends.12	  Depending	  upon	  the	  nature	  of	  substituents,	   they	   can	  adopt	  any	   one	   of	   the	   possible	   conformations	   in	   a	   given	  circumstances.	   Sugar	   derived	   amino	   acids	  with	   5,5-­‐	   and	   6,5-­‐	   bicyclic	   scaffolds	  have	   been	  reported	  as	  β-­‐turn	  inducers.13,	   14	   For	   example,	   as	   shown	   below,	   bicyclic	   sugar	   derived	  amino	  acid	   (SAA)	   2	  was	   incorporated	   to	  induce	  the	  bioactive	  conformation	   in	   small	   cyclic	  RGD	   (Arg-­‐Gly-­‐Asp)	   peptide	   analog	   3,	   which	   acts	   as	  selective	  antagonist	   of	  αvβ3	  integrins	  expressed	  on	  GM	  7373	  cells.15	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Figure	  1.2.	  Cyclic	  peptide	  3	   consists	  sugar	  amino	  acid	  derivative	  bicyclic	  scaffold	  2	   as	  a	  core	  structure	  	   Integrins	  are	  a	   large	   family	   of	   α/β	   heterodimeric	   transmembrane	   receptors	  comprise	  of	  glycoproteins	  that	  attach	  cells	  to	  extracellular	  matrix	  (ECM)	  proteins.	  Primary	  functions	   of	  integrins	  are	  attachment	  of	   the	   cell	   to	   the	   extracellular	   matrix,	   and	   signal	  transduction	  from	  the	  ECM	  to	  the	  cell.	  Many	  cells	  have	  multiple	  types	  of	  integrins	  on	  their	  surface,	   which	   involve	   in,	   along	   with	  fundamental	  cellular	   processes,	   various	   disease	  states	   such	   as	   tumors,	   immune,	   and	   inflammatory	   disorders.	   Constrained	   RGD	   analogs,	  with	   rigid	   bicyclic	   amino	   acid	   as	   an	   inducer	   of	   the	   desired	   conformation,	  have	   been	  reported	  as	   inhibitors	   of	  integrin	  receptors.	   Peptidomimetic	   RGD	   analog	   4	   with	  pyrroloazepinone	  core	  structure	  is	  a	  potent	  nonselective	  inhibitor	  of	  αvβ3	  (IC50	  =	  3.7	  nM,	  
Ki	  =	  3nM)	  and	  αvβ5	  (IC50	  =	  1.4	  nM).16	  
	  	  
	   5	  
αvβ3/αvβ5	  inhibitor	  IC50	  =	  3.7/1.4	  nM	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  αvβ5	  inhibitor	  IC50	  =	  4.1	  nM	  
	  
Figure	  1.3.	  Cyclic	  peptidomimetics	  4	  and	  5,	  αvβ5	  inhibitors	  	   	  Subsequent	   replacement	   of	   the	   pyrroloazepinone	   by	   (3R,	   6R,	   9S)	   3-­‐benzyl-­‐indolizidine-­‐2-­‐one	   provided	   αvβ5	   inhibitor	   5	   (IC50	   =	   4.1	   nM).17	   Constrained	  azabicycloalkanone	   amino	   acids	   such	   as	   6	   -­13	  have	  been	   reported	  as	  useful	  in	  the	  synthesis	  of	  peptidomimetics	  to	  induce	  beta	  turns.18 	  	  
	  
	  
Figure	   1.4.	   Various	   conformationally	   constrained	   azabicycloalkanone	   amino	   acids,	  potential	  inducers	  of	  desired	  conformations	  in	  peptidomimetics	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A	   cyclic	   vinyl	   amide	   scaffold	   16	  has	   been	   designed	  to	   mimic	   the	  segment	  Phe43-­‐Leu44	   of	   CD4	   15.	   CD4	   is	   a	   co-­‐receptor	   of	   a	   T-­‐cell	   receptor,	   which	   is	   responsible	  for	  recognition	  of	  antigens	  bound	  to	  major	  histocompatibility	  complex	  (MHC)	  molecules.19	  Its	  main	  function	  is	   to	   amplify	   the	   signal	   generated	   by	   the	  TCR	  by	   recruiting	   the	   enzyme	  known	  as	  tyrosine	  kinase	  lck,	  which	  is	  essential	  for	  activating	  many	  molecules	  involved	  in	  the	  signaling	  cascade	  of	  an	  activated	  T	  cell.	  	  
	  
	  




Figure	  1.6.	  Schematic	  representation	  of	  hydrogen	  bonding	  in	  18	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Bicyclic	  compound	  17	  is	  an	  example	  of	  beta	  strand	  mimetic.	  X-­‐ray	  crystal	  structure	  of	   thrombin	   complex	  with	   compound	  17	   revealed	   an	   anti-­‐parallel	   beta	   strand	   hydrogen	  bonds	  between	   the	  carbonyl	  oxygen	  and	   the	  amino	  nitrogen	  atom	  of	  bicyclic	  scaffold	  and	  the	  active	  site	  Ser214-­‐Gly216	  of	  thrombin’s	  S2	  subunit.20	  Hetero	  bicyclic	  compounds	  have	  also	   been	   used	   as	  β-­‐strand	  inducers.	   In	  tripeptide	  derivative	   of	   the	   bicyclic	   3,6-­‐diaminoquinolone	  18,	  hydrogen	  bonding	  scaffold	  induced	  a	  rigid	  β-­‐strand	  conformation	  in	  attached	  amino	  acids.21	  A	  hydrogen	  atom	  was	  required	  on	  the	  amino	  group	  at	  position	  3	  of	  the	   quinone	   scaffold	   for	   the	  formation	  of	   one	   of	   the	   necessary	   hydrogen	   bonds	   of	   the	  β-­‐strand	  conformation.	  
	  
Figure	   1.7.	   a)	   Schematic	   representation	   of	   anti-­‐parallel	   β-­‐strand	   hydrogen	   bonding	  between	   Aeruginosin	   98B	   (19)	   and	   trypsin.	   b)	   Schematic	   presentation	   of	   the	   hydrogen	  bonding	  between	  20-­22	  and	  thrombin.	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Octahydrindole	   scaffold	   in	   the	   natural	   product	   tetrapeptide	   orientates	   its	  pharmacophores	   in	  proximity	   to	   the	  active	   site	  of	  protease	  enzyme	  trypsin.	  X-­‐ray	   crystal	  structure	   of	  trypsin	  enzyme	   complex	   with	   the	  compound	  19	   revealed	   an	  extended	  H-­‐
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bonding	  pattern	  that	  is	  illustrative	  of	  anti-­‐parallel	  beta	  strand	  binding.22	  Compounds	  20-­22	  have	   diazabicyclic	   scaffold	   also	  show	  extended	   H-­‐bonding	   with	   the	   active	   site	   of	  thrombin.23	  Short	  peptide	  compounds	  23-­27,	  which	  contain	  5,6-­‐fused	  bicyclic	  amino	  acids	  with	  multiple	   hetero	  atoms	   as	   core	   structure,	  have	   been	  reported	  as	  excellent	  peptidomimetic	  inhibitors	  of	  serine	  proteases:	  trypsin,	  and	  thrombin	  in	  the	  nano-­‐molar	  range.24-­‐28	  
	  
Figure	   1.8.	   Compounds	   contain	   5,6-­‐fused	   bicyclic	   amino	   acid	   core	   structures	   with	  multiple	  heteroatoms	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Bicyclic	  amino	  acids	  in	  drug	  design	  and	  development	  	  Broad	  range	  of	  biological	  activities	  of	  bicyclic	  amino	  acids	  is	  being	  explored.	  Various	  bicyclic	  amino	  acids	  and	  their	  derivatives	  showed	  biological	  activity	  against	  inflammatory	  disorders,	   autoimmune	   disorders,	   cell	   proliferative	   disorders,	   epilepsy,	   faintness	   attacks,	  hypokinesia,	   cranial	   disorders,	   neurodegenerative	   disorders,	   depression,	   anxiety,	   panic,	  pain,	  arthritis,	  neuropathological,	  and	  sleep	  disorders.	  Bicyclic	  amino	  acids	  have	  also	  been	  used	   as	  core	  structures	   of	   drug	   molecules.	   For	   example,	   ACE	   inhibitors	   (26-­29)	  Trandolapril	  and	  Prindopril	  contain	  the	  bicyclic	  octahydrindole	  2-­‐carboxylic	  acid	  as	  a	  core	  structure,	  Quinapril	   contains	   tetrahydroisoquinolin-­‐3-­‐carboxylic	   acid,	   and	  Ramipril	   has	   a	  5,5	  fused	  bicyclo	  amino	  acid.	  	  
	  	  	  	  
	  Figure	  1.9.	  Some	  of	  the	  drug	  molecules	  that	  have	  constrained	  bicyclic	  amino	  acid	  as	  core	  structure	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Azabicycloalkane	   amino	   acid	   analogs	   30-­39	  have	   been	   reported	  as	   angiotensin	  converting	   enzyme	   (ACE)	   and	  neutral	  endopeptidase	   (NEP)	   inhibitors.	   ACE	   is	  an	  exopeptidase	  that	   catalyzes	   the	   conversion	   of	   angiotensin	   I	   to	   angiotensin	   II,	   a	   potent	  vasoconstrictor;	   also,	   degrades	   bradykinin,	   a	   potent	   vasodilator.	   These	   enzymes	   play	  an	  important	  role	   in	   blood	   pressure	  regulation,	   body	   fluid	   homeostasis,	   and	   cell	  growth.	  Hence	   inhibition	   of	   these	   enzymes	   is	   a	  main	  goal	   in	   the	   treatment	   of	   conditions	   such	   as	  heart	   failure,	   high-­‐blood	   pressure,	   diabetic	   neuropathy,	   and	   type-­‐2	   diabetes	   mellitus.	  Analogs	   of	   32	   (35-­38),	   which	  have	  oxygen	   or	   methylene	  group	  in	  place	  of	   sulfur	   also	   5	  membered	   ring	   in	   36	   and	   38,	   showed	  equivalent	  potency	  to	   32	   against	   ACE	   and	   NEP.	  Among	   all	   these	   azabicycloalkane	   amino	   acid	   analogs,	   compound	   30	   showed	  higher	  potency	  against	   both	   ACE	   and	   NEP.	   Compound	  39	   showed	  decent	  potency	  against	  ACE,	  but	  its	  activity	  against	  NEP	  is	  not	  that	  impressive.	  	   Azabicycloalkane	   amino	   acids	   40-­	   46,	   diazabicyclo	   alkane	   amino	   acids	   47-­	   54,	  and	  thia-­‐aza	  bicyclo	   alkane	   amino	   acids	  55-­	   58	   showed	   inhibitory	   activity	   against	   serine	  protease	   thrombin.	   Compound	   40	   showed	  decent	  activity	  against	   both	   thrombin	   and	  trypsin,	   with	   Ki	   =	   0.85	  nM	  and	   0.23	  nM	  respectively,	   but	   obviously	   selectivity	   was	  a	  big	  concern.	   Compound	   43	   with	  tetrahydro	  napthyl	   sulfate	   as	  R	  group	   showed	   6	   fold	  higher	  potency	  against	  thrombin	  compared	  to	  its	  counter	  parts	  44	  and	  45.33-­‐35	  Compound	  
46	   showed	   significant	   potency	   against	   thrombin	   with	   Ki	   =	   9	   nM,	   also	   exhibited	   20-­‐fold	  selectivity	  over	  trypsin.36	  Since	  41	  and	  46	  are	  slightly	  different,	  regarding	  substituents	  on	  bicyclic	   scaffold,	   it	   would	   be	  interesting	  to	  know	  the	  comparative	  selectivity	   in	   favor	   of	  thrombin	  over	  trypsin,	  but	  data	  are	  not	  available	  for	  trypsin.34 




Figure	  1.10.	  Bicyclic	  amino	  acid	  ACE	  and	  NEP	  inhibitors	  	  	  	  




Figure	  1.11.	  Azabicyclo	  amino	  acid	  derivative	  protease	  inhibitors	  	   Compounds	  47	  and	  48	  showed	  good	  potency	  against	  both	  thrombin	  and	  trypsin,	  but	  failed	   to	   show	   any	   selectivity.33	   Compounds	   49	   –	   52	   and	   58	   showed	  decent	  inhibitory	  activity	  against	  thrombin,	  but	  biological	  activity	  data	  against	  trypsin	  is	  not	  available.37-­‐44,	  46	  Compounds	   55	   and	   56,	   which	   differ	   with	   respect	   to	   the	   stereochemistry	   at	   C6	  position,	  appear	  to	   have	   some	   selectivity	   towards	   thrombin,	   but	   exhibiting	   moderate	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potency.45	   Conformationally	   constrained	   azabicycloalkane	   amino	   acids	   59-­	   63	  exhibited	  nanomolar	  range	  inhibitory	   activity	   against	   caspases1	   and	   caspase3.	   6-­‐aza-­‐piperdinoazipinone-­‐aspartate-­‐α-­‐aldehydes	  59	  and	  61	  are	  the	  most	  potent	  among	  all	  with	  
Ki	  =	  1nM	  for	  Caspase1.47,	  48	  Compound	  61	  inhibited	  both	  Caspase1	  and	  Caspase3	  with	  Ki	  =	  1nM	  and	  10	  nM	  respectively.49	  Compound	  62	  selectively	  inhibited	  caspase1	  with	  IC50	  =	  36	  nM,	  and	  compound	  63	  selectively	  inhibited	  caspase3	  with	  IC50	  =	  18	  nM.	  Caspase1	  belongs	  to	  a	  family	  of	  cystine	  proteases	  that	  always	  cleave	  peptide	  bonds	  following	  an	  aspartic	  acid	  residue.	  Caspase3	  has	  been	  identified	  as	  a	  mediator	  of	  apoptosis	  in	  mammalian	  cells.	  Over	  expression	   of	   both	   caspase1	   and	   3	   would	   kill	   cells	   indiscriminately.	   Inhibitors	  of	  caspases	  have	   been	   useful	   in	   the	   treatment	   of	   diseases	   such	   as	   rheumatoid	   arthritic,	  Alzheimer’s	  disease,	  amyotrophic	  lateral	  sclerosis	  (ALS),	  and	  Parkinson’s	  disease.	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Figure	  1.12.	  Some	  of	  the	  compounds	  that	  showing	  significant	  protease	  inhibitory	  action	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Figure	  1.13.	  Various	  GPCR	  ligands	  	   Various	  constrained	  unnatural	  bicyclic	  amino	  acid	  analogs	  have	  been	  explored	  as	  G	  protein-­‐coupled	   receptor	   (GPCR)	   ligands.	   G	   protein-­‐coupled	   receptors	   comprised	   of	  a	  large	  protein	   family	   of	   trance	   membrane	   proteins	   that	  receive	  chemical	   signals	   from	  outside	   the	   cell,	   and	  activate	  inside	   signal	   transduction	   pathways	   and	   cellular	   responses.	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GPC	   receptors	  involve	  in	  several	  diseases,	   and	   have	   become	   targets	   for	   almost	   30%	   of	  the	  medicinal	  drugs	   that	   are	  currently	  being	   used	  in	   the	   treatment	   of	   various	   diseases.	  When	   a	   ligand	   binds	   to	   the	   GPCR,	   it	   causes	   a	   conformational	   change	   in	   the	   GPCR,	   and	  activates	   G	   protein.	   Further	  effect	  depends	   on	   the	   G	   protein	   that	   involved	   in	   signal	  transduction	  or	  disease.	  Bicyclic	  scaffolds	  64	  and	  65	  act	  as	  TRH-­‐R1/2	  partial	  agonists	  with	  Ki	   1.4	  μM	  and	   1.5	  μM,	  respectively.50,	   51	   Compound	   66	   has	   shown	   antagonist	   activity	  against	   the	   Cholecystokinin	   (CCK1)	   receptor.	  Dihydroindolizidinone	  tripeptide	  mimic	   67	  acted	  as	  a	  specific	  neurokinin	  (NK1)	  receptor	  antagonist	  with	  Ki	  =	  79	  nM.54,	  55 	  
	  
Aeruginosins	  The	   novel	   bicyclic	   amino	   acid	   2-­‐carboxy-­‐6-­‐hydroxyocta-­‐hydrindole	   (Choi)	  is	  important	  motif	  commonly	   shared	   among	   aeruginosins.	   Aeruginosins	  are	  linear	   tetra-­‐peptides	  isolated	   from	  microcystic	  aeruginosa,	   which	   is	   the	   most	   common	   toxic	   cyano	  bacterium	   in	   eutrophic	   fresh	   water.37,	   57	   Cyanobacteria	  are	  prokaryotic	   photosynthetic	  microorganisms	  that	  are	  a	  rich	  source	  of	  a	  variety	  of	  structurally	  novel	  bioactive	  nitrogen	  compounds.	  Among	   the	  wide	   range	   of	   serine	  protease	   inhibitors	   found	   in	   cyanobacteria,	  aeruginosin	   298	   A,	   the	   first	   member	   of	   the	   family,	  was	   isolated	  by	   Murakama	   and	  co-­‐workers	  in	  1994.56	  In	  the	  span	  of	  a	  decade,	  continuous	  search	  for	  biologically	  active	  natural	  products	  resulted	  in	  isolation	  of	  20	  new	  aeruginosins	  that	  are	  structurally	  closely	  related.	  They	  were	   isolated	  from	   geographically	  different	  locations	   from	   different	   sources	   having	  no	  clear	  relationship	  to	  the	  Microcystis	  waterbloom.37,	  56-­‐66	  Regardless	  of	  diverse	  origin,	  all	  aeruginosin	   family	   members	  are	   comprised	  of	   the	  distinctive	  cis-­‐fused	   2-­‐
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carboxyperhydrindole	   as	   the	   core	   structure.	  With	   few	   exceptions,	   they	  exhibited	  varying	  degree	  of	  inhibitory	  activity	  against	  one	  or	  more	  serine	  proteases.	  Almost	  all	  aeruginosins	  showed	   in	   vitro	   activity	  mainly	   against	   serine	  proteases:	   Thrombin,	   Trypsin,	   and	   Factor	  VIIa.	   Some	   of	   the	   aeruginosins	   have	   also	   been	   evaluated	   against	   other	   enzymes,	   such	   as	  plasmin,	   chemotrypsin,	   elastase,	   and	  cystine	  protease	   papain.	   For	   simplification,	  generalized	  structure	  of	   aeruginosins	  virtually	  can	  be	  divided	   into	   four	   common	  portions:	  a	  C-­‐terminal	   guanidine	   containing	   group	   P1,	   a	   2-­‐carboxyperhydrindole	   core	   P2,	   a	   bulky	  hydrophobic	  amino	  acid	  P3	  and	  an	  N-­‐terminal	  hydroxy	  or	  acidic	  group	  P4.	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  1.14.	  Generalized	  structure	  of	  the	  aeruginosins	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Figure	  1.15.	  Natural	  product	  aeruginosins	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  Aeruginosin	   98A	   (69),	   aeruginosin	   98B	   (70),	   aeruginosin	   98C	   (71),	   and	  aeruginosin	  101	  (72)	  have	  three	  common	  subunits:	  P1	  basic	  guanidine	  group,	  O-­‐sulfate	  L-­‐Choi	   as	   P2,	   and	   D-­‐allo-­‐Ile	   as	   P3	   subunit.	   The	   fourth	   subunit	   is	   D-­‐Hpla	   with	  different	  substituents	  on	   the	   aromatic	   ring.	   They	   showed	   significant	   potency	   against	  thrombin,	   but	   they	   did	   not	   show	   any	   selectivity	   to	   thrombin	   over	   trypsin.	   Where	   as,	  aeruginosin	   98A	   and	   aeruginosin	   98B	   showed	   moderate	   selectivity	   in	   favor	   of	   trypsin.	  Presence	   of	   halo	  substituents	  on	   the	   aromatic	   ring	   of	   D-­‐Hpla	   seems	   to	   be	  causing	  loss	   of	  selectivity.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   
	  
	  
Figure	  1.16.	  Aeruginosins	  that	  differ	  at	  P3	  resudue	  	   Compounds	  73-­77	  contain	  argal	  group	  in	  cyclic	  form	  (6	  membered)	  as	   P1	   moiety,	  and	  O-­‐sulfated	  D-­‐Hpla	  P4	  residues	  as	  common	  subunits.	  Aeruginosins	  89A	  and	  89B	  have	  D-­‐Leu,	  while	  other	   three	  compounds:	  aeruginosins	  102A,	  102B,	  and	  103A	  have	  D-­‐Tyr	  as	  hydrophobic	   residue	   P3.	   Except	   103A,	   in	  which	   hydroxy	   group	   is	   protected	   as	   an	   ethyl	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ether,	   all	   other	   four	   compounds	   showed	   excellent	   activity	   against	   both	   thrombin	   and	  trypsin.	  Above	  details	  indicate	  that	  modifications	  in	  P3-­‐P4	  portion	  don’t	  have	  much	  impact	  on	  potency.	  
	  
Figure	  1.17.	  Aeruginosin	  298	  B,	  aeruginosin	  EI461,	  and	  dysinosins	  with	  cyclic	  ariginine	  analog.	  	   Aeruginosin	  298B	  and	  aeruginosin	  EI461,	  without	  P1	  subunit,	   lost	   their	  biological	  activity.	  It	  clearly	  indicates	  that	  P1	  basic	  unit	  with	  guanidine	  group	  is	  essential	  for	  activity.	  P1	   basic	   subunit	   and	   O-­‐Me-­‐O-­‐SO3-­‐	   D-­‐lysinic	   acid	   influencing	   biological	   activity	   in	  compounds	  dysinosin	  A	   (80),	   Chlorodysinosin	   A	   (81),	   and	  dysinosin	  C	   (83).	   Particularly,	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Chloro	   substituent	   in	   Chlorodysinosin	   A	   appears	   to	   be	   responsible	   for	  high	  activity.	  Aeruginosin	  205	  B	  has	  2-­‐chloro	  substituted	  D-­‐Leu	  showed	  significant	  potency.	  Hanessian	  and	  group	  have	  explained	  this	  phenomenon	  as	  chlorine	  effect. 	  	  
	  
	  
Figure	  1.18.	  Comparison	  of	  the	  compounds	  with	  variations	  in	  P1,	  P2,	  P3	  and	  P4	  subunits.	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Figure	  1.19.	  Schematic	  representation	  of	  thrombin	  active	  site	  bind	  to	  aeruginosin	  298A	  	   X-­‐ray	   crystal	   structures	   of	   the	   enzyme	   in	  complex	  with	   several	   aeruginosin	   family	  members	   provided	   valuable	   information	   about	   enzyme–inhibitor	   interactions.56	   Most	   of	  the	   aeruginosin	   family	  members	   interacted	  with	   the	   active	   site	   of	   thrombin	   enzyme	   in	   a	  similar	  way	  and	   revealed	   the	   most	  important	  regions	   of	   the	   thrombin	   active	   site	   for	  inhibition.	  As	  shown	  in	  the	  above	  figure	  subsites	  S1,	  S2,	  and	  S3	  are	  crucial	  for	  the	  biological	  activity.	  The	  S1	  subsite,	  also	  known	  as	  the	  specificity	  pocket,	  can	  recognize	  and	  engage	  in	  ionic	   interactions	   with	   inhibitors	   containing	   C-­‐terminal	   guanidine	   group	   P1.	   Carboxy	  hydrindole	  core	  structure	  P2	  residue	   fits	   into	  S2	  packet.	  Hydrophobic	  amino	  acid	  residue	  P3	  and	  hydroxyphenyllactic	  acid	  (Hpla)	  P4	  interact	  with	  S3	  subsite.	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So	  far,	  X-­‐ray	  crystal	  structures	  of	  thrombin	  enzyme	  complex	  with	  Aeruginosin	  298A,	  dysinosin	   A,	   oscillarin,	   and	   chlorodysinosin	   A	  have	   been	   reported.	   All	   of	   them	   revealed	  similar	   binding	   modes	   in	   the	   active	   site,	   with	   slight	   variations	   in	   orienting	   polar	  substituents.68-­‐71	   there	   are	   no	   hydrogen	   bonds	   between	   the	   hydroxy	   groups	   of	   the	  octahydrindole	   and	   thrombin	   active	   site	   is	   evident.	   Therefore,	   we	   can	   conclude	   that	  hydroxy	  groups	  on	  bicyclic	  core	  structure	  have	  no	  influence	  on	  biological	  activity.	  Sandler	  and	  co-­‐workers	  have	  reported	  X-­‐ray	  crystal	  structure	  of	  trypsin	  complex	  with	  aeruginosin	  98B.	  	  They	   speculated	   that	   the	   selectivity	   of	   6-­‐O-­‐	   sulfate	   aeruginosin	  98B	   to	   trypsin	  over	  thrombin	  might	  be	  due	  to	  the	  sulfate	  group	  that	  was	  projected	  into	  the	  hydrophobic	  pocket	  of	  thrombin	  active	  site.	  Whereas	  in	  case	  of	  trypsin	  the	  sulfate	  group	  of	  aeruginosin	  98B	  was	  projected	  in	   to	   the	   solution	  present	  out	   side	   the	   active	   site.72	   Bicyclic	   amino	   acid	  core	  structure	  is	  essential	  to	  bring	  rigidity	  and	  stability	  to	  aeruginosins. 	  	  
Synthesis	  of	  bicyclic	  amino	  acid	  core	  structure	  of	  aeruginosins:	  	  	  	   Thrombosis	   and	   related	   complications	   are	   major	   causes	   of	   potentially	   fatal	  cardiovascular	   and	   cerebrovascular	   disease	   throughout	   the	   world.73	   Current	  anticoagulation	   therapies,	   such	   as	   the	   administration	   of	   heparins	   and	   coumarins,	   are	  limited	   by	   narrow	   therapeutic	   windows,	   severe	   side	   effects,	   and/or	   the	   need	   for	  parenteral	   administration.74	   Intensive	   efforts	   are	   being	   made	   to	   develop	   new	  anticoagulants	  relying	  on	  direct	  inhibition	  of	  coagulation	  enzymes.75-­‐78	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The	   central	   role	   of	   thrombin	   in	   the	   blood	   coagulation	   cascade	   has	   made	   it	   an	  attractive	   target	   for	   the	   development	   of	   antithrombotic	   drugs.79-­‐84	   Thus,	   aeruginosins,	  which	   exhibited	   inhibitory	   potency	   against	   blood	   coagulation	   factors,	   have	   become	  attractive	   small-­‐molecule	   targets	   in	   the	   search	   for	   new	   anticoagulants.	   For	   some	   of	   the	  members	  of	   aeruginosin	   family,	   stereochemistry	  assignments	  were	  not	   fully	  established.	  Several	  members	  were	  revised,	  and	  still	  being	  revised.	  A	  structural	  revision	  of	  aeruginosin	  205B	  has	  been	  reported	  in	  2010.92	  	  	  Synthesis	   of	  constrained	  bicyclic	   amino	   acid	   core	  structure,	   L-­‐Choi,	   achieved	   by	  Bonjoch	  et	  al.	  Absolute	  stereochemistry	  of	  L-­‐Choi	   (104)	  has	  also	  been	  established	  as	  (2S,	  3aS,	   6R,	   7aS)-­‐6-­‐hydroxy	   octahydrindole-­‐2-­‐carboxylic	   acid.	   The	   azabicyclic	   core	   unit	  synthesis	   commenced	   from	   aromatic	   amino	   acid	   92.	   Birch	   reduction	   followed	   by	   acidic	  cleavage	   of	   the	   enol	   ether,	   and	   Michael-­‐type	   addition	   of	   the	   pendant	  amine	  nucleophile	  provided	  a	  mixture	  of	   isomers	  94	  and	  95.	  After	  benzylation	  of	  acid	  and	  amine	  groups,	  benzyl	  ester	  was	  converted	  to	  methyl	  ester	  on	  treatment	  with	  methanol	   in	  the	  presence	  of	  acid	  resin.	  On	  treatment	  with	  concentrated	  acid,	  98a	  would	  be	  converted	  to	  more	   stable	   and	   desired	   bicyclic	   intermediate	   98b.	   Benzyl	  deprotection	  and	   acetyl	  protection	   of	  secondary	  amine	   followed	  by	   reduction	   of	  keto	  function	  group	  yielded	  desired	  bicyclic	  core	  structure	  104	  (scheme	  1.1).85	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Scheme	  1.1.	   Synthesis	  of	  methyl	  6-­‐hydroxy-­‐cis-­‐octahydrindole-­‐2-­‐carboxylate	  derivatives	  by	  Bonjoch	  et	  al	  	  	  




Scheme	  1.2.	  Synthesis	  of	  aeruginosin	  298A	  by	  Bonjoch	  et	  al	  	  	  After	   establishing	   the	   stereochemistry	   of	   bicyclic	   core	  structure,	   total	   synthesis	   of	  aeruginosin	   298A	  was	   pursued	  starting	   from	  keto	  intermediate	   98b.86,87	   For	   the	  convenience,	   benzyl	  protection	  was	   removed,	   and	   Boc	  protection	  was	   installed	  for	  secondary	   amine.	   Various	   reduction	   conditions	  were	   attempted	  to	   establish	   optimizing	  reduction	  conditions.	  Bulky	  reducing	  regent	  L-­‐selectride	  gave	  desired	  6R	  stereochemistry	  for	  alcohol.	  Removal	  of	  Boc	  protection	  followed	  by	  BOP	  mediated	  coupling	  with	  Boc-­‐D-­‐Leu-­‐
	   27	  
OH	  resulted	  in	  dipeptide	  107.	  Following	  the	  same	  protocol,	  coupling	  of	  protected	  hydroxy	  phenyllactic	   acid	  with	   intermediate	  107	   resulted	   in	  tripeptide	  108.	   Hydrolysis	   of	  methyl	  ester,	   and	   coupling	   with	   L-­‐Arg	   (NO2)-­‐OMe.HCl	   followed	   by	   removal	   of	   the	   protecting	  groups	  by	  hydrolysis	  afforded	  aeruginosin	  298A.	  	  	  
	  	  	  
Scheme	  1.3.	  Synthesis	  of	  bicyclic	  core	  structure	  by	  Shibasaki	  et	  al	  	   	  In	  2004,	  Shibasaki	  and	  group	  reported	  a	  versatile	  synthetic	  process	  for	  aeruginosin	  298A	   as	   well	   as	  several	  analogs.	   Stereochemistry	   of	   all	   the	   centers	  was	   controlled	  by	  catalytic	  asymmetric	  phase-­‐transfer	  reaction	  promoted	  by	  two-­‐center	  asymmetric	  catalysts	  
112a	   &	   112b.	   Asymmetric	  epoxidation	  promoted	   by	   a	   Lanthanide-­‐BINOL	   complex.89-­‐90	  Synthetic	   strategy	   for	   bicyclic	   amino	   acid	   core	  structure	  114	   and	   then	   aeruginosin	  298A	  was	   commenced	  from	   compound	   111.	   Reaction	   between	  enolate	  of	   110	   and	   allyl	  bromide	   derivative	   111	   in	   the	   presence	   of	   10	  mol%	   of	   112a	   as	   a	   catalyst	   to	  give	  113	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(80%	  yield	  and	   88%	   ee).	   Ketal	  deprotection	  and	   subsequent	   intramolecular	   Michael-­‐type	  addition	  afforded	  bicyclic	  undesired	  ketone	  98a	  and	  desired	  ketone	  98b	   in	  2:1	  ratio.	  Then,	  acid	  treatment	  of	  98a,	  following	  the	  method	  previously	  reported	  by	  Bonjoch	  and	  co-­‐workers,	  yielded	  98b	  in	  78%	  yield. 
	  
Scheme	  1.4.	  Synthesis	  of	  119	  by	  Shibasaki	  et	  al	  	  	  	  
	  	  
Scheme	  1.5.	  Synthesis	  of	  aeruginosin	  298A	  by	  Shibasaki	  et	  al	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Allylglycine	   precursor	   116	  was	   obtained	  from	   compound	   111	   and	   allyl	   bromide	  
115	  by	  utilizing	  asymmetric	  phase-­‐transfer	  alkylation	  in	  the	  presence	  of	  112b.	  Functional	  group	  deprotection,	   Boc	   protection,	  hydroxylation	  by	   asymmetric	  hydroboration	  followed	  by	   oxidation	   yielded	   117,	   which	   further	   transformed	   into	   guanidine	   intermediate	   118.	  Peptide	   coupling	   with	   114	   followed	   by	   Boc	   removal	   afforded	   dipeptide	   L-­‐Choi-­‐Argal	  intermediate	   119	   in	   72%	   yield.	   Asymmetric	  epoxidation	  of	   120	   gave	   121,	   and	   then	  converted	   to	   amide	  122	   on	   coupling	  with	   D-­‐4,	   5-­‐dehydroleucine-­‐OtBu.	   Reduction	   of	   the	  double	  bond	  by	   catalytic	  hydrogenation,	  protection	  of	   alcohol,	   and	   cleavage	  of	   the	  t-­‐butyl	  ester	  gave	  Hpla-­‐Leu	  fragment	  123.	  Coupling	  with	  119	  in	  the	  presence	  of	  HATU	  yielded	  124	  and	  followed	  by	  methyl	  ester	  removal	  afforded	  aeruginosin	  298A.	  	  	  
	  
Figure	  1.20.	  Some	  of	  the	  synthetic	  aeruginosin	  analogs	  	  Total	   synthesis	   of	   other	   members	   of	   aeruginosin	  family	  also	  being	   pursued	  by	  several	   research	   groups.	   Hanessian	   and	   co-­‐workers	   via	   ring-­‐closing	  metathesis	   achieved	  first	   synthesis	   of	   a	   potent	   thrombin	   and	   factor	   VIIa	   inhibitor	   dysinosin	   A.	   This	   method	  conformed	  the	  structure	  of	  dysinosin	  A	  and	  provided	  an	  entry	   into	  the	  novel	  5-­‐hydroxy	  L-­‐
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Choi	   and	   Adc	   structural	  motifs.	   Allylglutamate	   precursor	  129,	   which	   is	   readily	   available	  from	  L-­‐glutamic	  acid	  in	  high	  yields,	  converted	  to	  pyroglutamate	  130,	  followed	  by	  reduction	  of	   the	   lactam	   function	  group	  with	   super-­‐hydride	   (LiBHEt3)	   and	   O-­‐acetylation	  of	  the	  intermediate	  provided	   131	   in	   85%	   yield.	   Alkylation	   of	   the	   N-­‐acyl	  iminium	  ion	  intermediate	  was	   achieved	  in	   the	   presence	   of	   allylbutyl	  stannane	  and	  BF3.Et2O	   to	  give	  132,	   and	   then	   treatment	   with	   Grubb’s	   second-­‐generation	   catalyst	   in	  refluxing	   dichloromethane	   yielded	   bicyclic	   alkene	   133.	   Trans	   dihydroxylation	   and	  protecting	  group	  manipulation	  gave	  5-­‐hydroxy	  L-­‐Choi	  derivative	  135	  in	  44%	  overall	  yield	  from	  129.	  	  	  
	  	  
	  
Scheme	  1.6.	  Synthesis	  of	  Choi	  analog	  135	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So	   far,	   limited	  number	  of	  total	  syntheses	  of	  natural	  product	   aeruginosins	  has	  been	  achieved.	   Quite	   a	   few	   numbers	   of	  synthetic	  aeruginosin	   analogs	   were	   reported.	  Considerable	  amount	  of	  variations	   made	   to	   P1,	   P3	   and	   P4	   residues,	   but	  very	  limited	  number	   of	   efforts	  have	   been	   made	  to	   synthesize	   aeruginosin	   analogs,	   with	   various	  synthetic	  octahydrindole	  analogs	  as	  a	   core	  structure.	  Compounds	  125,	  126,	   and	  127	   are	  the	  representative	  members	  of	  aeruginosin	  analogs	  with	  different	  bicyclic	  scaffold.	  Among	  all	  the	  natural	  product	  aeruginosins	  and	  their	  synthetic	  analogs,	  compound	  125	  is	  the	  most	  potent	  thrombin	  inhibitor	  reported	  to	  date.	  Several	  research	  groups	  have	  also	  reported	  the	  synthesis	  of	  various	  Choi	  analogs	  and	  their	  improved	  synthetic	  methodologies.	  Some	  of	  the	  significant	  methodologies	  have	  been	  discussed	  below.	  	   Tandem	   catalysis	  has	   been	   utilized	  to	  perform	  Diels-­‐Alder	   reaction	   between	  bromoacrolein	   and	   furan	   followed	   by	   Mukaiyama	   Aldol	   reaction	   affording	   bromo	  intermediate	  139,	  with	  decent	  stereo	  selectivity	  (dr.	  5:1,	  ee.	  86:14).91-­‐93	  Then	  treated	  139	  with	   potassium	   tertiary	  butoxide	  to	  obtain	  intermediate	   140.	  	   Compound	   140	  was	  treated	  with	  m-­‐CPBA	  to	  form	  epoxide,	   then	   H2/Pd	   reducing	   conditions	  were	   employed	  to	  reduce	   α,	   β-­‐	   unsaturation,	   followed	   by	   K2CO3	   treatment	   provided	   lactone	   intermediate	  
141.	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Scheme	  1.7.	  Synthesis	  of	  bicyclic	  core	  structure	  149	  by	  Carreira	  et	  al	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Azalactone	  143	  was	  obtained	  by	   treating	  141	  with	  bulky	  base	  and	  142.	  Lactone	  of	  
143	  was	  opened,	  and	  the	  resulting	  azide	  was	  reduced	  to	  amine	  and	  protected	  using	  CbzCl.	  Epoxide	  was	   opened	  selectively	   using	   low-­‐valent	   Ti	   reagents	   followed	   by	   resulting	   2o	  alcohol	  was	  protected	  selectively	  as	  acetate,	  then	  3o	  alcohol	  was	  removed	  by	  following	  the	  previously	   reported	  procedure.	  Deprotection	  of	  Cbz	  group	   followed	  by	  TMSOTf	  mediated	  nucleophilic	  opening	  yielded	   dihydroxy	   octahydrindole	   149,	   the	   core	   structure	   of	  MicrocineSF608.93	  	  	  
Synthesis	  of	  other	  bicyclic	  amino	  acids	  
	   Many	  other	  bicyclic	  scaffolds	  that	  closely	  resemble	  Choi	  analogs,	   like	  tetrahydroxy	  octahydrindole	  155,	  consist	  in	  natural	  product	  alkaloids.	  Some	  of	  the	  hydroxy	  indolizidine	  alkaloids	   noteworthy	   to	   mention	   are:	   lentiginosine,	   an	   amyloglucosidase	   inhibitor;	  swainsonine,	   an	   α-­‐	  mannosidase	   inhibitor;	   castanospermine,	   an	   α-­‐	  glucosidase	   inhibitor.	  Synthesis	   of	  tetrahydroxy	  octahydrindole	   155	   and	   other	   prominent	   bicyclic	   amino	   acid	  analogs,	   mainly	   azabicyclo	   amino	   acids	   and	   bicyclic	   scaffolds	   with	   more	   than	  one	  heteroatom,	  have	  been	  discussed	  below.94	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Scheme	  1.9.	  Synthesis	  of	  various	  azabicyclo	  amino	  acids	  165-­168	  starting	  from	  156	  	  	   	  	  












Scheme	  1.11.	  Synthesis	  of	  175	  from	  proline	  derivative	  179	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Scheme	  1.12.	   Synthesis	  of	   azabicyclo	  amino	  acids	  192-­	  194	   from	  proline	  via	   ring	   cyclo	  alkene	  metathesis	  	   Synthesis	   of	   bicyclic	   amino	   acid	   179	   from	  keto	  diester	   175	   in	   6	   steps	  has	   been	  reported.	  Protection	  of	  keto	  function	  group	  using	  ethylene	  glycol	   followed	  by	  reduction	  of	  ester	   function	   groups	   in	   the	   presence	   of	   mild	   reducing	   agent	   DIBAL-­‐H	   at	   low	  temperatures	  afford	  dialdehyde	  intermediate	   176,	   then	   let	   it	   react	   with	   2	  equivalents	  of	  
162	   and	  undergo	  reduction	  to	   give	  178.	  Deprotection	  of	   the	   amine	  group	  and	  keto	  group	  followed	  by	  cyclization	  under	  mild	  basic	  conditions	  yielded	  179.98 	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Scheme	  1.13.	  Synthesis	  of	  various	  bicyclo	  amino	  acids	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   Bicyclic	  amino	  acids	  192-­194	  can	  be	  obtained	  from	  proline	  derivative	  180.	  Cis-­‐vinyl	  proline	   (5R)	   182	  was	   synthesized	  by	   oxidation	   of	  180	   and	  addition	  of	  bis	  (trimethylsilyl)	  acetylene	   followed	   by	  lindar’s	  reduction	  provides	   182.	   Diene	   188	  was	   obtained	  from	  compound	   182	   by	   treating	   with	   compound	   183.	   Then,	   ring	   closing	   metathesis	  conditions	  were	   employed	  to	  compound	  188	   to	  yield	  bicyclic	   scaffold	   192.	   Following	  similar	   reaction	   conditions,	  azabicyclic	  amino	   acid	   analogs	   193	   and	   194	  have	   been	  synthesized	  from	  compound	  182,	  as	  shown	  in	  scheme	  12.98	  	   Azabicyclo	   compounds	   203-­	   206	  have	   been	   obtained	  from	   a	   homo	   allyl	   proline	  derivative	  195,	  which	  is	  a	  homologue	  of	  compound	  182.98,	  99	  Similar	  reaction	  conditions	  as	  used	   in	  scheme	  1.12	  were	   employed	  to	  compound	  195	   to	   obtain	  corresponding	  products	  
199,	  200,	  201,	   and	  202.	  Finally,	  ring	  closing	  metathesis	  of	  dienes	  199-­202	  using	  reagent	  
190	  yields	  their	  corresponding	  bicyclic	  scaffolds	  203-­	  206,	  as	  shown	  in	  scheme	  13. 	   Synthesis	  of	  hetero	  bicyclic	  amino	  acid	  analogs	  oxa-­‐quinolidine	  ester	  209	  and	  aza-­‐quinolidine	  ester	  211	  were	  obtained	  from	  Boc-­‐serinyl-­‐allylglycne	  methyl	  ester	  207.	  Thia-­‐quinolinidine	   ester	  214	  was	   obtained	  form	   S-­‐(trityl)-­‐N-­‐(Boc)cysteinyl-­‐allylglycine	  methyl	  ester	  212	  in	  excellent	  yield.100 	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Introduction	  	  Conformationally	   constrained	   bicyclic	   amino	   acids	   and	   their	   derivatives	  are	  prominent	  biologically	  active	  compounds	  in	  the	  treatment	  of	  many	  diseases.1,	  2	  Various	  bicyclic	   and	  hetero	   bicyclic	  amino	   acids	  are	  essential	  core	   structures	   of	  many	  biologically	  active	   natural	   products	   and	  peptidomimetics.3-­‐5	   Rigid	   bicyclic	   amino	   acid,	   2-­‐carboxy-­‐6-­‐hydroxyl	   octahydrindole	   (L-­‐Choi)	   or	   its	  close	  derivative	   (Fig.	   2.1),	   is	   a	   core	   structure	   of	  aeruginosin	   family	   members.	   Aeruginosins	  are	  the	   tetrapeptide	   natural	   product	   serine	  protease	   inhibitors	   isolated	   from	   the	  marine	   sponges	   and	   cyanobacterial	   water	   blooms.	  Almost	  all	  the	  members	  of	  aeruginosin	  family	  showed	  promising	  inhibitory	  activity	  against	  thrombin,	  trypsin,	  and	  some	  of	  them	  also	  showed	  significant	  activity	  against	  factor	  VIIa.6-­‐16	  	  	  
	  
Figure	  2.1.	  Aeruginosin	  family	  members	  having	  different	  bicyclic	  core	  structures	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   Thrombin	   and	  factor	  VIIIa	   play	  crucial	  role	   in	   blood	   clotting	   cascade;	   Thrombin	  converts	   soluble	   fibrinogen	   to	   fibrin	   and	   favors	   the	   formation	   of	   cross-­‐linked	   bonds	  between	   fibrin	  molecules	   to	   form	  a	  mesh	  that	   stabilizes	   blood	   clot,	   also	   activates	   several	  coagulation	   factors.17	   Excessive	  generation	  of	   fibrin	   due	   to	   activation	   of	   the	   coagulation	  cascade	   leads	   to	   thrombosis;	   hence,	   inhibition	  of	   thrombin	   is	   essential	   in	   the	  prevention	  and	   treatment	   of	   cardiovascular	   and	   cerebrovascular	   diseases.	   According	   to	   American	  heart	   association	   statistics,	   36.2	   %	   of	   people	   are	   suffering	   from	   cardiovascular	   or	   its	  related	   diseases;	   each	   year	   831,000	   people	  are	   succumbed	  to	   death.	  Current	  major	  anticoagulants	   have	  many	  disadvantages,	   such	   as	  narrow	  therapeutic	  windows,	   side	   effects,	   and	   need	   for	   parenteral	   administration.	   For	   example,	   direct	  thrombin	   inhibitors	   such	   as	   hirudin,	   dabigatran,	   and	   melagatran	  are	  suffered	  from	  expeditious	  clearance	  by	   kidneys,	   and	   accumulation	  of	   these	  drugs	   leads	   to	  renal	   impairments.17	   There	   is	   a	   greater	   urgency	   to	   develop	   new	   class	   of	   anticoagulants	  that	  overcome	  disadvantages	  of	  currently	  available	  drugs.	  	  
	  
Figure	  2.2.	  Some	  of	  the	  synthetic	  aeruginosin	  analogs	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Figure	  2.3.	  Different	   core	   structures	  of	  natural	  product	   aeruginosins	  7-­	  9	   and	   synthetic	  Choi	  analogs	  10	  –	  13	  	   Promising	  thrombin	  inhibitory	  activity	  of	  aeruginosins	  made	  them	  attractive	  small	  molecule	  drug	  targets.	  Constrained	  cis-­‐fused	  bicyclic	  amino	  acid	  core	  structure	  is	  vital	  to	  keep	   the	  pharmacophores	   in	  appropriate	  position	   for	  maximum	   interactions	  with	  active	  site	  of	  protease	  enzyme.	  Several	  research	  groups	  have	  been	  pursuing	  synthesis	  of	  various	  synthetic	  aeruginosin	  analogs	  (Fig.	  2.2)	  and	  their	  core	  structure	  L-­‐Choi	  analogs	  (Fig.	  2.3)	  to	  improve	  efficiency	  and	  selectivity.18-­‐24	  Our	  research	  group	  has	  been	  pursuing	  synthesis	  of	  bicyclic	  amino	  acid	  core	  structure	  Choi	  analogs	  with	  oxygen	  substituent	  in	  6-­‐membered	  ring,	  and	  also	  with	  varying	  number	  and	  position	  of	  hydroxy	  groups	  on	  pyrano	  ring.25-­‐28	  	   Generalized	   structure	   of	   aeruginosins	   comprised	   of	   4	   common	   portions:	   a	   C-­‐terminal	   guanidine	   containing	   group	   P1,	   a	   2-­‐carboxyperhydrindole	   core	   P2,	   a	   bulky	  hydrophobic	  amino	  acid	  P3	  and	  an	  N-­‐terminal	  hydroxy	  or	  acidic	  group	  P4	  (Fig.	  2.4a).	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Figure	  2.4.	  X-­‐	  ray	  crystal	  structure	  of	  aeruginosin	  298	  A	  in	  complex	  with	  thrombin.29	  	   X-­‐ray	   crystal	   structures	   of	   the	   enzyme	   in	  complex	  with	   several	   aeruginosin	   family	  members	  provide	  valuable	  information	  about	  enzyme–	  inhibitor	  interactions.	  Aeruginosins	  interact	   with	   the	   active	   site	   of	   thrombin	   enzyme	   in	   a	   similar	   way,	   and	  reveal	  the	  most	  important	  regions	  of	  the	  thrombin	  active	  site	  for	  inhibition	  are	  the	  S1,	  S2,	  and	  the	  d-­‐S3	   subsites,	   as	   shown	   in	   the	   above	   (figure	   2.4a).	   Figure	   2.4b	   represents	   X-­‐ray	   crystal	  structure	  of	  aeruginosin	  298	  A	   in	  complex	  with	   thrombin.	  The	  S1	  subsite,	   also	  known	  as	  the	   specificity	   pocket,	   can	  recognize	  and	   engage	   in	   ionic	   interactions	  with	   inhibitors	   that	  contain	  C-­‐terminal	   guanidine	   group.	  Carboxy	  hydrindole	   core	  structure	  residueP2	   fit	   into	  S2	   packet.	   Hydrophobic	   amino	   acid	   P3	  residue	  and	   hydroxyphenyllactic	   acid	  (Hpla)	  accommodate	  into	  S3	  subsite.	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   Since	   both	   thrombin	   and	   trypsin	   belong	   to	   the	   same	   protease	   family	   (serine	  protease),	   their	   binding	   sites	   closely	   resemble	   with	   slight	   variations.	   Because	   of	   this	  proximity	   of	   binding	   sites,	   structurally	   closely	   related	   aeruginosin	  members	   inhibit	   both	  thrombin	   and	   trypsin	   without	   any	   distinction.	   Inhibition	   of	   thrombin	  renders	  disease	  curative	   effect,	   but	   inhibition	   of	   trypsin	   does	   not	   have	  any	  positive	  medication	  effect.	  Further,	  it	  might	  disrupt	  normal	  functions	  of	  trypsin,	  might	  lead	  to	  unnecessary	  side	  effects.	  	   So	   far,	   limited	  number	  of	  total	  syntheses	  of	  natural	  product	   aeruginosins	  has	  been	  achieved.	  Quite	  a	  few	  synthetic	  analogs	  of	  aeruginosin	  family	  members	  were	  reported	  with	  variations	   in	   P1,	   P3	   and	   P4	   residues,	   but	   a	   limited	   number	   of	   efforts	  have	   been	  made	  to	  synthesize	   aeruginosin	   analogs	   with	   various	   synthetic	   octahydrindole	   analogs	   as	   a	   core	  structure.	   Compounds	  4	   -­	   6	   are	   the	  representative	  members	   of	   aeruginosin	   analogs	  with	  different	   bicyclic	   scaffold.6,	   26	   Wang	   and	  group	  have	   reported	   synthesis	   and	   biological	  activity	  evaluation	  of	   compounds	   5	   and	   6.	   Compound	   5,	   which	   has	   opposite	  stereochemistry	   at	  ring	  junction	   of	   bicyclic	   core	  structure	  compared	   to	  naturally	  isolated	  aeruginosin	  members,	  however,	  showed	  reduced	   inhibitory	  activity	  against	   thrombin	  (24	  μg/L),	   its	   selectivity	   to	   thrombin	   is	   remarkable;	   showed	  no	   inhibitory	  activity	  has	   shown	  against	   trypsin.	   Among	   all	   the	  natural	  product	   aeruginosins	   and	   their	   synthetic	   analogs,	  compound	  4,	  reported	  by	  Hanessian	  and	  the	  group,	  is	  the	  most	  potent	  thrombin	  inhibitor	  reported	   to	   date.	   They	   have	   claimed	   that	   its	   activity	   is	  due	  to	   the	   presence	   of	   chlorine	  substitution	   on	   P3	   residue,	   and	   they	   have	   termed	   it	   as	   chlorine	   effect.	   Several	   research	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Scheme	  2.1.	  Synthesis	  of	  Choi	  analog	  27	  by	  Carreira	  et	  al	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   Eric	  M.	  Carreira	  and	  group	  have	  reported	  the	  synthesis	  of	  dihydroxy	  octahydrindole	  
27,	   which	   is	   the	   core	   structure	   of	   MicrocineSF608.24	   Tandem	   catalysis,	  has	   been	  utilized	  to	  perform	  Diels-­‐Alder	   reaction	   between	   bromoacrolein	   and	   furan.	   Followed	   by	  Mukaiyama	  Aldol	   reaction	  afforded	  bromo	   intermediate	  17	  with	  decent	  stereo	   selectivity	  (dr.	   5:1,	   ee.	   86:14).	   Then	   treated	  compound	  17	   with	   potassium	   tertiary	  butoxide	  to	  obtain	  intermediate	   18.	  Compound	   18	  was	   treated	  with	  m-­‐CPBA	  to	  form	  epoxide,	   then	   H2/Pd	   reducing	   conditions	  were	   employed	  to	   reduce	   α,β-­‐	  unsaturation,	   then	   resulting	  compound	  was	   treated	  with	   K2CO3	   to	   obtain	   lactone	  intermediate	  19.	  	   Azalactone	   21	  was	   obtained	  by	   treating	   compound	   19	  with	  bulky	  base	  and	  compound	  20.	   Lactone	   of	   intermediate	   21	  was	   opened,	   and	   the	  resulting	  azide	  was	  reduced	  to	  amine	  and	  protected	  using	  CbzCl.	  Epoxide	  was	  selectively	  opened	   using	   low-­‐valent	   Ti	   reagents	   followed	   by	   resulting	   2o	   alcohol	  was	   protected	  as	  acetate.	   Then	   3o	  alcohol	  was	   removed	  by	   following	   a	   previously	   reported	  procedure.	  Deprotection	   of	   Cbz	   group	   followed	   by	   TMSOTf	   mediated	   nucleophilic	  opening	  yielded	  dihydroxy	  octahydrindole	  27,	  the	  core	  structure	  of	  MicrocineSF608.	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Figure	  2.5.	  Synthesis	  of	  O-­‐Choi	  analogs	  30	  and	  31	  achieved	  from	  glucose	  28,	  and	  32	  and	  
33	  achieved	  from	  mannose	  29.	  	  	  G	  Wang	  and	  coworkers	  have	  previously	  reported	  the	  synthesis	  of	  ring	  oxygenated	  Choi	  analogs	  30	  –	  33	   (fig	  2.5)	   from	  D-­‐glucose	  or	  D-­‐mannose	  as	  starting	  material.25-­‐28	  As	  shown	   in	   scheme	   2.2,	   O-­‐Choi	   analogs	   49	   and	   50	  were	   synthesized	  starting	   from	   D-­‐mannose	  28.	  27Protection	  of	  all	  the	  five	  hydroxy	  groups	  by	  treating	  D-­‐mannose	  with	  acetic	  anhydride,	   then	   removal	   of	  anomeric	  acetyl	   group,	   followed	   by	  deprotection	  of	   hydroxy	  groups	  under	  basic	  reaction	  conditions	  yields	  tetrahydroxy	  sugar	  derivative	  37.	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Scheme	  2.2.	  Synthesis	  of	  O-­‐Choi	  variants	  49	  and	  50	  from	  D-­‐mannose	  29	  	   Spatially	   closer	   C2,	   C3	   hydroxy	   groups	   of	  intermediate	  37	  were	   protected	  as	   5	  membered	  cyclic	  acetal,	  and	  C4,	  C6	  hydroxy	  groups	  were	  protected	  as	  6	  membered	  cyclic	  acetal.	  Less	  stable	  5	  membered	  cyclic	  acetal	  was	  opened	  under	  acidic	  conditions,	  resulting	  mixture	   of	   regio-­‐isomers	   40,	   and	   41	  were	   reacted	  with	   benzyl	   bromide	   to	   afford	  intermediate	   42.	   Benzylidine	  protection	  was	   removed	  under	   acidic	   conditions	   and	   then	  again	   protected	   as	  mesylates.	  Primary	  mesylate	  was	   displaced	  with	   bromine	  to	  give	  intermediate	  43.	  Compound	  45	  reacted	  with	  N-­‐Boc	  dimethylaminomalonate	  in	  the	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presence	  of	  basic	  conditions,	  and	  then	  treated	  with	  sodium	  hydroxide,	  followed	  by	  refluxed	  conditions	  were	  employed	  to	  yield	  ring	  oxygenated	  bicyclic	  amino	  acids	  49	  and	  50. 
	  	  
Results	  and	  discussion	  We	  aimed	  to	  synthesize	  O-­‐Choi	  analog	  60	  starting	  from	  α-­‐	  methoxy	  glucopyranose	  51,	   as	   shown	   in	   fig	   6.	   Retro	   synthetic	   strategy	   for	   the	   synthesis	   of	   O-­‐Choi	   analog	  60	   is	  shown	   above.	   Final	   target	   compound	   60	   can	   be	   achieved	   from	   6-­‐bromo-­‐sugar	  intermediate	  59	   by	   coupling	  with	   glycine.	   	   	   Intermediate	  59	   can	   be	   achieved	   from	   edo-­‐epoxide	  sugar	  intermediate	  54	  by	  reduction	  of	  epoxide	  followed	  by	  protection	  of	  resulted	  hydroxy	   group	   and	   acetal	   deprotection.	   Intermediate	   5430	   can	   be	   obtained	   from	   α-­‐	  methoxy	   glucopyranose	  51	   in	   3	   steps.	  We	  planned	   to	   remove	  C3	   hydroxy	   group	   in	   final	  compound	  60	  by	  making	  epoxide	   intermediate	  and	  then	  subjected	   to	  reductive	  opening.	  Epoxide	   intermediate	  54	   can	  be	  obtained	   in	  quantitative	  yields	  without	  any	  purification	  required.	  	  
	  	  
Figure	  2.6.	  Strategy	  for	  the	  synthesis	  of	  60	  from	  D-­‐glucopyranose	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Scheme	  2.3.	  Strategy	  for	  the	  synthesis	  of	  60	  	  	   Synthesis	   of	   60	   commenced	   from	   α-­‐methoxy	   glucopyranose	   51	   as	   the	   starting	  material.	   Hydroxy	   groups	   at	   C4,	   C6	  were	  protected	  as	   benzylidine	   acetal	   by	   reacting	  with	  dimethyl	  benzylidine	  acetal	   in	   the	  presence	  of	  catalytic	  acidic	  conditions.	  7	  mol	  %	  of	  PTSA	  is	  enough	  to	  catalyze	  the	  reaction	  and	  complete	  in	  20	  min	  of	  time.	  Both	  the	  C2	  and	  C3	  hydroxy	   groups	  were	   protected	  as	   tosyl	   groups,	   and	   in	   the	   following	   step,	   treatment	   of	  ditosyl	   compound	  53	   with	   sodium	  methoxide	  yields	   endo-­‐2,	   3epoxide	  54	   in	   quantitative	  yield.30	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Scheme	  2.5.	  Synthesis	  of	  bromo	  intermediate	  59	  	  	   Several	   attempts	  were	   made	  to	  get	  cyclized	  product	   60	   from	  bromo	  intermediate	  
59,	   but	   they	   were	   successful.	   Attempted	   to	   couple	   59	   with	   N-­‐(diphenylmethylene)	  ethyl	  glycinate	  in	   the	   presence	   of	   non-­‐nucleophilic	   bases.	   Sodium	   hydride	   as	   a	   base	   in	  combination	  with	  toluene	  as	  a	  solvent	  was	  also	  unsuccessful	  at	  various	  temperature	  (room	  temperature	  to	  reflux)	  conditions	  (Scheme	  7).	  At	  room	  temperature,	  starting	  material	  was	  remained	  unreactive,	  and	  at	  higher	  temperature	  SM	  was	  slowly	  consumed	  but	  decomposed	  into	   several	   compounds.	   Potassium	  tertiary	  butoxide	  in	  t-­‐butanol	  was	   used	  as	   a	   milder	  base	   for	   a	   couple	   of	   times,	   but	   it	  was	  not	  fruitful.	   Cyclization	  step	  was	   also	  pursued	  with	  Boc-­‐protected	  ethylglycinates	  63	  and,	  but	  failed	  to	  cyclize.	  Finally,	  tried	  with	  benzyl	  amine	  to	  get	  6,	  4-­‐	  fused	  bicyclic	  compound	  66	  was	  attempted	  once,	  but	  unsuccessful.	  	  	  
























Scheme	  2.8.	  Alternative	  strategies	  for	  the	  alkylation,	  which	  were	  not	  tried	  	  	   In	   conclusion,	   epoxide	   intermediate	   54	   and	   bromo	   intermediate	   59	   have	   been	  synthesized	  in	  decent	  yields.	  In	  future,	  different	  reaction	  conditions	  (as	  shown	  in	  scheme	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α-­	  methoxy	  4,6-­benzylidine	  2,3-­ditosylate	  glucopyranose	  52.	  15	   g	   of	  52	   was	   taken	   in	   500	  mL	   of	   round	   bottom	   flask,	   1.2	   eq	   of	   benzaldehyde	  dimethyl	  acetal	  and	  7mol	  %	  of	  PTSA	  was	  added	  to	  the	  round	  bottom	  flask.	  Directly	  put	  on	  rotary	   evaporator	   at	   50	   oC	   and	   started	   removing	   methanol	   formed	   in	   the	   reaction.	   As	  reaction	   progressing,	   white	   solid	   starting	  material	   increasingly	   dissolved	   and	  methanol	  continuously	   removed.	   After	   25	   min	   reaction	   was	   done,	   and	   quenched	   with	   sodium	  bicarbonate.	   Diluted	   the	   reaction	  mixture	  with	   500	  mL	   of	  water	   product	  was	   extracted	  into	  600	  mL	  of	  ethyl	   acetate	  by	  washing	  water	  phase	  with	   three	  equal	  portions	  of	   ethyl	  acetate.	   Collective	   organic	   phase	   was	   dried	   over	   sodium	   sulfate	   and	   concentrated	   on	  rotary	   evaporator,	   then	   kept	   under	   nitrogen	   flow	   for	   4	   hrs	   to	   remove	  DMF	   as	  much	   as	  possible.	   	  Product	  was	   recrystallized	   from	  ethanol.	  White	   solid	  needle	   like	  crystals,	  with	  MP	  166-­‐167	  oC,	  obtained	  in	  quantitative	  yield.	  	  
1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  7.49	  (m,	  2H),	  7.37	  (m,	  3H),	  5.53	  (s,	  1H),	  4.79	  (d,	  1H,	  J	  =	  3.9	  Hz),	  4.29	  (m,	  1H),	  3.92	  (t,	  1H,	   J	  =	  9.2	  Hz),	  3.77	  (m,	  2H),	  3.62	  (td,	  1H,	   J	  =	  9.0,	  3.9	  Hz),	  3.47	  (m,	  4H),	  2.85	  (s,	  1H),	  2.36	  (d,	  1H,	  J	  =	  9.2	  Hz).	  13C	  NMR	  (400	  MHz,	  CDCl3)	  δ134.5,	  126.7,	  125.8,	  123.7,	  99.4,	  97.2,	  78.4,	  70.3,	  69.2,	  66.4,	  59.8,	  53.0	  
	  
α-­	  methoxy	  4,6-­benzylidine	  2,3-­ditosylate	  glucopyranose	  53.	  15	   g	   of	   53	   was	   dissolved	   in	   40	   mL	   of	   pyridine,	   2.5	   eq	   of	   TsCl	   was	   added	   and	  reaction	  mixture	  was	  stirred	  at	  60	  C	  for	  36	  h.	  Reaction	  mixture	  was	  diluted	  with	  500	  mL	  of	  water,	   product	  was	   extracted	   into	   700	  mL	   of	   dichloromethane	   by	  washing	  water	   phase	  with	   three	   equal	   proportions,	   then	   collected	   organic	   phase	   was	   washed	   with	   brine	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fallowed	  by	  dried	  over	  sodium	  sulfate.	  After	  concentrating	  the	  organic	  phase	  on	  15	  g	  of	  52	  was	   taken	   in	  500	  mL	  of	  round	  bottom	  flask,	  1.2	  eq	  of	  benzaldehyde	  dimethyl	  acetal	  and	  7mol	  %	  of	  PTSA	  was	  added	  to	  the	  round	  bottom	  flask.	  Directly	  put	  on	  rotary	  evaporator	  at	  50	   oC	   and	   started	   removing	   methanol	   formed	   in	   the	   reaction.	   As	   reaction	   progressing,	  white	  solid	  starting	  material	   increasingly	  dissolved	  and	  methanol	  continuously	  removed.	  After	   25	   min	   reaction	   was	   done,	   and	   quenched	   with	   sodium	   bicarbonate.	   Diluted	   the	  reaction	  mixture	  with	  500	  mL	  of	  water	  product	  was	  extracted	  into	  600	  mL	  of	  ethyl	  acetate	  by	   washing	   water	   phase	   with	   three	   equal	   portions	   of	   ethyl	   acetate.	   Collective	   organic	  phase	  was	   dried	   over	   sodium	   sulfate	   and	   concentrated	   on	   rotary	   evaporator,	   then	   kept	  under	   nitrogen	   flow	   for	   4	   hrs	   to	   remove	   DMF	   as	   much	   as	   possible.	   	   Product	   was	  recrystallized	  from	  ethanol.	  White	  solid	  needle	  like	  crystals,	  with	  MP	  166-­‐167	  oC,	  obtained	  in	  quantitative	  yield.,	  product	  was	  kept	  under	  nitrogen	  flow	  for	  4	  h	  to	  remove	  pyridine	  as	  much	  as	  possible,	  then	  product	  was	  recrystallized	  from	  ethyl	  acetate	  and	  dried	  on	  vacuum	  pump	  for	  10	  h.	  White	  solid	  product	  with	  MP	  125-­‐126	  oC	  was	  obtained	  in	  quantitative	  yield.	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α-­	  methoxy	  4,6-­benzylidine	  2,3-­epoxy	  glucopyranose	  54.	  15	   g	   of	  54	  was	   taken	   in	   1	   L	   round	   bottom	   flask,	   150	  mL	   of	   THF	  was	   added	   and	  stirred	  for	  5	  min,	  then	  cooled	  it	  to	  0	  oC.	  3	  eq	  of	  sodium	  methoxide	  dissolved	  in	  methanol	  was	  added	  slowly	  for	  5	  min.	  After	  30	  min	  of	  stirring,	  THF	  was	  removed	  on	  15	  g	  of	  52	  was	  taken	  in	  500	  mL	  of	  round	  bottom	  flask,	  1.2	  eq	  of	  benzaldehyde	  dimethyl	  acetal	  and	  7mol	  %	  of	  PTSA	  was	  added	  to	  the	  round	  bottom	  flask.	  Directly	  put	  on	  rotary	  evaporator	  at	  50	  oC	  and	  started	  removing	  methanol	   formed	  in	  the	  reaction.	  As	  reaction	  progress,	  white	  solid	  starting	  material	  increasingly	  dissolved	  and	  methanol	  continuously	  removed.	  After	  25	  min	  reaction	  was	  done,	  and	  quenched	  with	  sodium	  bicarbonate.	  Reaction	  mixture	  was	  diluted	  with	  500	  mL	  of	  water,	  and	  product	  was	  extracted	  into	  600	  mL	  of	  ethyl	  acetate	  by	  washing	  water	  phase	  with	  three	  equal	  portions	  of	  ethyl	  acetate.	  Collective	  organic	  phase	  was	  dried	  over	  sodium	  sulfate	  and	  concentrated	  on	  rotary	  evaporator,	  then	  kept	  under	  nitrogen	  flow	  for	  4	  hrs	   to	   remove	  DMF	  as	  much	  as	  possible.	   	  Product	  was	  recrystallized	   from	  ethanol.	  White	  solid	  needle	  like	  crystals,	  with	  MP	  166-­‐167	  oC,	  obtained	  in	  quantitative	  yield.	  	  
1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  7.51	  (dd,	  1H,	  J	  =	  6.8,	  2.7	  Hz),	  7.37	  (m,	  3H),	  5.58	  (s,	  1H),	  4.90	  (d,	  1H,	  J	  =	  2.7	  Hz),	  4.25	  (dd,	  1H,	  J	  =	  10.1,	  5.0	  Hz),	  4.09	  (td,	  1H,	  J	  =	  9.8,	  5.0	  Hz),	  3.97	  (dd,	  1H,	  J	  =	  9.1,	  1.2	  Hz),	  3.69	  (t,	  1H,	  J	  =	  10.3	  Hz),	  3.51	  (m,	  5H).	  13C	  NMR	  (400	  MHz,	  CDCl3)	  δ134.5,	  126.7,	  125.8,	  123.7,	  99.4,	  97.2,	  78.4,	  72.3,	  69.2,	  66.4,	  59.8,	  53.0	  
	  
α-­	  methoxy	  4,6-­benzylidine	  3-­hydroxy	  glucopyranose	  55.	  5	  g	  of	  compound	  55	  was	  dissolved	  in	  50	  mL	  of	  THF	  in	  500	  mL	  round	  bottom	  flask,	  cooled	   to	  0	   oC,	  3	  eq	  of	   lithium	  aluminum	  hydride	  (LAH)	  was	  added	  carefully	  and	  stirred	  reaction	  for	  6	  h	  at	  0	  oC.	  Excess	  of	  LAH	  was	  initially	  quenched	  by	  150	  mL	  of	  ethyl	  acetate,	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and	   then	   sodium	   sulfate	   hepta	   hydrated	   was	   added	   and	   stirred	   for	   5	   h	   until	   reaction	  mixture	  turned	  to	  white.	  Filtered	  the	  mixture	  through	  filter	  paper	  and	  repeatedly	  washed	  the	   solid	   residue	  with	   excess	  of	   ethyl	   acetate	   for	   several	   times.	  Product	  was	  purified	  by	  column	  chromatography	  using	  15%	  of	  ethyl	  acetate	   in	  hexane.	  White	  solid	  product	  with	  MP	  120-­‐121	  oC	  was	  obtained	  in	  90%	  of	  yield,	  then	  dried	  the	  product	  on	  vacuum	  pump	  for	  8	  h	  and	  proceeded	  to	  next	  step.	  1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  7.47	  (dt,	  1H,	  J	  =	  7.1,	  1.8	  Hz),	  7.29	  (m,	  3H),	  5.52	  (d,	  1H,	  J	  =	  1.4	  Hz),	  4.66	  (d,	  1H,	  J	  =	  3.9	  Hz),	  4.24	  (ddd,	  1H,	  J	  =	  8.7,	  5.2,	  2.6	  Hz),	  4.14	  (td,	  1H,	  J	  =	  9.9,	  5.3	  Hz),	  4.04	  (td,	  1H,	  J	  =	  3.6,	  1.6	  Hz),	  3.68	  (td,	  J	  =	  10.1,	  1.4	  Hz,	  1H),	  3.46	  (dt,	  1H,	  J	  =	  9.5,	  2.0	  Hz),	  3.29	  (s,	  2H),	  3.13	  (dd,	  1H,	  J	  =	  6.8,	  1.5	  Hz),	  2.05	  (m,	  1H),	  1.86	  (m,	  1H).	   13C	  NMR	   (400	  MHz,	  CDCl3)	  δ	  137.8,	  129.2,	  128.4,	  126.8,	  102.1,	  98.7,	  79.8,	  69.5,	  65.0,	  58.3,	  55.5,	  35.7	  	  	  
α-­	  methoxy	  4,6-­benzylidine	  3-­benzyl	  glucopyranose	  56	  5	   g	   of	  56	   was	   dissolved	   in	   10	  mL	   of	   DMF,	   cooled	   to	   0	   oC,	   and	   1.5	   eq	   of	   sodium	  hydride	  was	  added,	  followed	  by	  1.5	  eq	  of	  benzyl	  bromide	  was	  added	  drop	  wise.	  Reaction	  was	   done	   in	   6	   h	   at	   0	   oC,	   then	   reaction	   mixture	   was	   diluted	   with	   250	   mL	   of	  dichloromethane	   followed	  by	  250	  mL	  of	  water,	  water	  phase	  was	  washed	  with	   two	  more	  times	   with	   150	   mL	   of	   dichloromethane	   each.	   Collective	   organic	   phase	   was	   dried	   over	  sodium	  sulfate	  and	  concentrated	  on	  rot	  vap,	  and	  then	  kept	  under	  nitrogen	  flow	  for	  4	  h	  to	  remove	   DMF	   as	   much	   as	   possible	   and	   the	   impurities	   were	   removed	   by	   column	  chromatography	   using	   8	   %	   of	   ethyl	   acetate	   in	   hexane.	   White	   solid	   with	   MP	   80-­‐81	   oC	  product	  was	  obtained	  in	  89	  %	  of	  yield.	  	  1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  7.52	  (m,	  2H),	  7.36	  (m,	  8H),	  5.57	  (s,	  1H),	  4.84	  (q,	  1H,	  J	  =	  12.8	  Hz),	  4.73	  (d,	  1H,	  J	  =	  4.6	  Hz),	  4.47	  (td,	  1H,	  J	  =	  10.0,	  5.3	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Hz),	  4.347	  –	  4.30	  (dd,	  1H,	  J	  =	  10.3,	  5.3	  Hz),	  3.98	  (q,	  1H,	  J	  =	  3.1	  Hz),	  3.72	  (m,	  2H),	  3.42	  (s,	  3H),	  2.22	  (m,	  1H),	  1.93	  (ddd,	  1H,	  J	  =	  14.9,	  4.6,	  3.5	  Hz).	  	  13C	  NMR	  (400	  MHz,	  CDCl3)	  δ	  136.4,	  135.1,	  126.3,	  125.6,	  125.4,	  124.8,	  124.46,	  123.6,	  99.5,	  95.2,	  77.8,	  69.4,	  67.6,	  66.9,	  55.5,	  52.9,	  31.8	  
	  
α-­methoxy	  3-­benzyl,	  4,	  6-­dihydroxy	  glucopyranose	  57.	  5	  g	  of	  starting	  material	  57	  was	  dissolved	  in	  30	  mL	  of	  95%	  of	  acetic	  acid,	  stirred	  for	  36	  h	  at	   room	   temperature,	   then	  diluted	   the	   reaction	  mixture	  with	  250	  mL	  of	  water	  and	  started	   neutralizing	   acetic	   acid	   by	   adding	   sodium	   bicarbonate	   slowly	   until	   no	   froth	   is	  formed.	  Product	  was	  extracted	   into	  ethyl	  acetate.	  Organic	  phase	  was	  purified	  by	  column	  chromatography	  using	  30%	  ethyl	  acetate	  in	  hexane.	  Colorless	  semisolid	  product	  was	  dried	  on	  vacuum	  pump	  for	  8h.	  The	  product	  yield	  is	  75%.	  1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  7.34	  (m,	  5H),	  4.80	  (d,	  1H,	  J	  =	  11.3	  Hz),	  4.73	  (d,	  1H,	  J	  =	  4.5	  Hz),	  4.38	  (d,	  1H,	  J	  =	  11.6	  Hz),	  3.87	  (m,	  4H),	  3.60	  (ddd,	  1H,	  J	  =	  10.6,	  9.7,	  3.7	  Hz),	  3.36	  (s,	  3H),	  2.70	  (d,	  1H,	  J	  =	  10.5	  Hz),	  2.33	  (ddd,	  1H,	  J	  =	  15.2,	  2.8,	  1.2	  Hz),	  2.24	  (m,	  1H),	  1.84	  (s,	  1H),	  1.76	  (ddd,	  1H,	  J	  =	  4.5,	  3.4,	  0.9	  Hz),	  1.71	  (m,	  1H).	  	  
13C	  NMR	  (400	  MHz,	  CDCl3)	  δ	  135.8,	  126.3,	  125.8,	  125.7,	  95.2,	  70.6,	  68.2,	  66.0,	  65.3,	  60.8,	  53.1,	  29.0	  
	  
α-­methoxy	  3-­benzyl,	  4,	  6-­dimesylate	  glucopyranose	  58.	  3	  g	  of	  58	  was	  dissolved	  in	  20	  mL	  of	  THF,	  cooled	  to	  0	  oC,	  3eq	  of	  methane	  sulfonile	  chloride	  and	  3	  eq	  of	  triethyl	  amine	  added,	  and	  reaction	  mixture	  was	  stirred	  for	  8	  h	  at	  0	  oC.	  THF	  was	  removed	  on	  rotary	  evaporator,	  and	  then	  solid	  residue	  was	  diluted	  with	  250	  mL	  of	  water	   and	   200	  mL	   of	   dichloromethane.	   Product	  was	   extracted	   into	   dichloromethane	   by	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washing	  water	  phase	  two	  more	  times.	  Collective	  organic	  phase	  was	  concentrated,	  and	  the	  product	  was	  purified	  by	  column	  chromatography	  using	  12%	  of	  ethyl	  acetate	  in	  hexane	  and	  dried	   on	   vacuum	   pump.	   Colorless	   semisolid	   product	  was	   obtained	   in	   82%	   of	   yield.	   	   1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  7.34	  (m,	  5H),	  4.73	  (ddd,	  1H,	  J	  =	  12.7,	  6.0,	  2.8	  Hz),	  4.47	  (m,	  4H),	  4.13	  (q,	  H,	  J	  =	  3.5	  Hz),	  3.36	  (s,	  3H),	  3.05	  (s,	  2H),	  2.99	  (s,	  2H),	  2.24	  (ddd,	  H,	  J	  =	  15.1,	  3.8,	  1.4	  Hz),	  1.86	  (ddd,	  1H,	  J	  =	  15.0,	  4.8,	  3.2	  Hz)	  13C	  NMR	  (400	  MHz,	  CDCl3)	  δ	  138.2,	  128.6,	  128.1,	  128.0,	  98.3,	  75.0,	  71.9,	  71.6,	  68.4,	  64.0,	  56.0,	  39.0,	  37.7,	  32.3	  
	  
α-­	  methoxy	  3-­benzyl,	  4-­mesylate	  6-­bromo	  glucopyranose	  59.	  2	  g	  of	  starting	  material	  59	  was	  dissolved	  in	  6	  mL	  of	  DMSO,	  6	  eq	  of	  sodium	  bromide	  salt	  was	  added	  and	   stirred	   for	  24	  h	  at	  60	   oC,	   and	   then	   the	   reaction	  mixture	  was	  diluted	  with	  200	  mL	  of	  water	  and	  150	  mL	  of	  dichloromethane.	  Water	  phase	  was	  washed	  two	  more	  times	   with	   100	   mL	   of	   dichloromethane	   each	   time.	   Collective	   organic	   phase	   was	  concentrated	   on	   rotary	   evaporator,	   and	   then	   the	   product	   was	   purified	   by	   column	  chromatography	   using	   15%	   ethyl	   acetate	   in	   hexane.	   Colorless	   semi	   solid	   product	   was	  dried	  on	  vacuum	  pump	  for	  10h.	  Product	  was	  obtained	  in	  60	  %	  of	  yield.	  1H	  NMR	  (400	  MHz,	  CDCl3)	  δ	  7.34	  (m,	  5H),	  4.88	  (m,	  1H),	  4.73	  (m,	  14H),	  4.56	  (d,	  1H,	  J	  =	  11.9	  Hz),	  4.45	  (ddd,	  1H,	  J	  =	  8.7,	  5.5,	  2.6	  Hz),	  4.12(q,	  1H,	  J	  =	  3.6	  Hz),	  3.67	  (dt,	  1H,	  J	  =	  11.2,	  3.5	  Hz),	  3.57(m,	  1H),	  3.41(s,	  3H),	  3.15	  –	  2.96	  (s,	  3H),	  2.32	  –	  2.18	  (ddd,	  1H,	  J	  =	  14.9,	  4.1,	  1.5	  Hz),	  1.89	  (ddd,	  1H,	  J	  =	  15.0,	  4.9,	  3.4	  Hz).	  	  13C	  NMR	  (400	  MHz,	  CDCl3)	  δ	  138.7,	  128.6,	  128.1,	  128.0,	  98.2,	  77.9,	  72.6,	  71.62,	  65.0,	  56.0,	  39.2,	  33.5,	  32.3	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